
Loading, please wait...

Loading, please wait...

Researchers have recently introduced the iGABASnFR2 GABA sensor, a second-generation genetically encoded tool designed to monitor GABAergic inhibition with unprecedented precision. While the first-generation sensor enabled initial studies, it often struggled with low signal-to-noise ratios and slow kinetics. Consequently, the team employed near-saturation mutagenesis to refine the protein structure. This breakthrough allows clinicians and researchers to observe inhibitory neurotransmission in vivo with much higher clarity.
The updated iGABASnFR2 GABA sensor offers a 4.1-fold improvement in sensitivity compared to its predecessor. Moreover, it features a 30% faster rise time, making it ideal for capturing rapid synaptic events. Specifically, the binding affinity remains within a range that accurately reflects physiological GABA fluctuations at the synapse. Furthermore, the scientists identified a negative-going variant, iGABASnFR2n, which decreases fluorescence upon GABA binding. This additional tool helps scientists corroborate findings by providing a reverse-response signal.
Initial in vivo testing has already yielded significant results in specialized neural tissues. In the retina, iGABASnFR2 enabled the first successful measurements of direction-selective GABA release. Additionally, imaging in the somatosensory cortex revealed the sensor\'s ability to report volume-transmitted GABA following whisker stimulation. Therefore, these improvements suggest that iGABASnFR2 will become a standard tool for mapping complex inhibitory circuits in real-time. This technology holds great potential for understanding disorders linked to GABAergic dysfunction, such as epilepsy and schizophrenia.
The iGABASnFR2 sensor provides 4.1 times more sensitivity and 30% faster kinetics than the original iGABASnFR. These upgrades allow for significantly better signal-to-noise ratios during live brain imaging.
iGABASnFR2n is a negative-going sensor that dims when GABA binds to it. Researchers use it alongside the positive-going sensor to confirm that observed fluorescence changes truly represent GABA dynamics rather than imaging artifacts.
While primarily a research tool, it provides critical insights for neurology, psychiatry, and ophthalmology. It specifically aids in studying how inhibitory signals govern motion sensitivity in the eye and sensory processing in the brain.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a recommendation for any specific technology. Always refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


iGABASnFR2 is an improved genetically encoded sensor for GABA, offering 4.1-fold better sensitivity and faster kinetics for advanced in vivo neural imaging....
5 months ago

A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today

Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today

A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today